The Renal Denervation Buzz: Separating Fact From Myth

This year’s EuroPCR conference, held in Paris in May, was definitely the coming out party for renal denervation (RDN), highlighting what many clinicians and industry executives point to as the next potential blockbuster device product market. In that way, RDN is following in the footsteps of transcatheter aortic valves (TAVI) and drug-eluting stents, both of which were unveiled at previous EuroPCR meetings and remain important topics today, with numerous sessions on both at this year’s conference.

But renal denervation, used to treat hypertension, was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic (several of which were company-sponsored). In...